[{"id":"c67cb0cc-4062-4cc7-ac4c-e0358ba638bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06986174","created_at":"2025-06-28T16:12:40.055Z","updated_at":"2025-06-28T16:12:40.055Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT06986174","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" TP53 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-05-22"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"a65eaf0b-f986-4662-a858-795fc0730939","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273139","created_at":"2021-01-18T20:45:24.651Z","updated_at":"2025-02-25T15:43:52.361Z","phase":"Phase 2","brief_title":"Ibrutinib + Venetoclax in Untreated WM","source_id_and_acronym":"NCT04273139","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 mutation","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 06/06/2022","primary_completion_date":" 06/06/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-11"},{"id":"7f3be9ed-280b-4ee8-a27b-1fa29dec3944","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506373","created_at":"2025-02-25T16:37:04.959Z","updated_at":"2025-02-25T16:37:04.959Z","phase":"Phase 2","brief_title":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","source_id_and_acronym":"NCT03506373","lead_sponsor":"Mayo Clinic","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Ninlaro (ixazomib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 03/11/2026","study_completion_date":" 03/11/2026","last_update_posted":"2025-02-07"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"BGB-3111-402","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2025-02-25T17:02:16.646Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102 - BGB-3111-402","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"},{"id":"13809b89-05e8-41ef-8215-b7d1aaa392e9","acronym":"NCI-2018-01880","url":"https://clinicaltrials.gov/study/NCT03884998","created_at":"2021-01-18T19:08:46.177Z","updated_at":"2025-02-25T17:36:15.593Z","phase":"Phase 1","brief_title":"Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03884998 - NCI-2018-01880","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/26/2019","start_date":" 02/26/2019","primary_txt":" Primary completion: 07/16/2025","primary_completion_date":" 07/16/2025","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-01-29"},{"id":"99c5ce8b-5c38-453f-ad28-f12ae4fd578b","acronym":"BGB-11417-203","url":"https://clinicaltrials.gov/study/NCT05952037","created_at":"2023-07-20T14:08:47.056Z","updated_at":"2025-02-25T17:39:02.716Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05952037 - BGB-11417-203","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-01-29"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"447ed126-6f5f-4987-b043-27e335f9b442","acronym":"C1763102","url":"https://clinicaltrials.gov/study/NCT05602363","created_at":"2024-01-29T15:19:20.293Z","updated_at":"2025-02-25T14:09:14.782Z","phase":"Phase 1","brief_title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05602363 - C1763102","lead_sponsor":"Carna Biosciences, Inc.","biomarkers":" PLCG2","pipe":" | ","alterations":" PLCG2 mutation","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docirbrutinib (AS-1763)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-11-01"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"d062a33d-5d42-4b72-844d-d38648c52ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464200","created_at":"2022-02-25T20:53:07.117Z","updated_at":"2025-02-25T14:51:50.702Z","phase":"Phase 1","brief_title":"19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers","source_id_and_acronym":"NCT04464200","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-08-23"},{"id":"d6470e31-1ef9-400d-8e4a-687104d9ddb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03277729","created_at":"2021-01-18T16:11:11.702Z","updated_at":"2024-07-02T16:34:26.876Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT03277729","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" CD20 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • MB-106"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 11/16/2037","study_completion_date":" 11/16/2037","last_update_posted":"2024-06-12"},{"id":"573d49f4-aa69-4732-80f5-94630ed62694","acronym":"BELLWAVE-003","url":"https://clinicaltrials.gov/study/NCT04728893","created_at":"2021-01-28T12:53:09.367Z","updated_at":"2024-07-02T16:34:37.168Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","source_id_and_acronym":"NCT04728893 - BELLWAVE-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • CCND1 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • CCND1 overexpression","tags":["TP53 • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 04/05/2021","start_date":" 04/05/2021","primary_txt":" Primary completion: 03/19/2027","primary_completion_date":" 03/19/2027","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2024-06-07"},{"id":"8258969e-d88e-4ec9-8ff8-f46b03ce6829","acronym":"SGR-1505-101","url":"https://clinicaltrials.gov/study/NCT05544019","created_at":"2022-09-16T14:56:40.430Z","updated_at":"2024-07-02T16:34:37.249Z","phase":"Phase 1","brief_title":"Study of SGR-1505 in Mature B-Cell Neoplasms","source_id_and_acronym":"NCT05544019 - SGR-1505-101","lead_sponsor":"Schrödinger, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SGR-1505"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 04/10/2023","start_date":" 04/10/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-07"},{"id":"255cb565-f80f-4c68-9621-5cff2388d8ef","acronym":"NX-5948-301","url":"https://clinicaltrials.gov/study/NCT05131022","created_at":"2022-07-08T17:55:02.950Z","updated_at":"2024-07-02T16:34:59.140Z","phase":"Phase 1","brief_title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT05131022 - NX-5948-301","lead_sponsor":"Nurix Therapeutics, Inc.","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexobrutideg (NX-5948)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"2389ac55-3a18-481d-8919-40b11f2cb668","acronym":"NCI-2017-01069","url":"https://clinicaltrials.gov/study/NCT03192397","created_at":"2021-01-18T15:44:50.740Z","updated_at":"2024-07-02T16:35:00.229Z","phase":"Phase 1/2","brief_title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT03192397 - NCI-2017-01069","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/21/2027","study_completion_date":" 05/21/2027","last_update_posted":"2024-05-29"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"dd7ff569-d80c-47b3-9966-fc0126c7d73b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04263480","created_at":"2021-01-18T20:43:06.789Z","updated_at":"2024-07-02T16:35:03.965Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT04263480","lead_sponsor":"Christian Buske","biomarkers":" CD20 • MYD88 • CXCR4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • carfilzomib"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-14"},{"id":"5c1628c8-1205-4db1-a7b7-2787115fd94d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620903","created_at":"2021-01-18T17:47:32.533Z","updated_at":"2024-07-02T16:35:04.143Z","phase":"Phase 2","brief_title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT03620903","lead_sponsor":"Christian Buske","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-13"},{"id":"68c8de81-678c-4539-bf83-7836e390592f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01788020","created_at":"2021-01-18T07:53:54.903Z","updated_at":"2024-07-02T16:35:04.236Z","phase":"Phase 3","brief_title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT01788020","lead_sponsor":"University of Ulm","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-05-13"},{"id":"ee25e9e3-0db7-4fcb-a64c-11f94e17e205","acronym":"VIWA-1","url":"https://clinicaltrials.gov/study/NCT05099471","created_at":"2021-10-29T14:53:17.774Z","updated_at":"2024-07-02T16:35:04.092Z","phase":"Phase 2","brief_title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05099471 - VIWA-1","lead_sponsor":"University of Ulm","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2024-05-13"},{"id":"c0c1d749-be49-44e4-a22c-cd71bfbd84c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04191187","created_at":"2021-01-18T20:25:39.923Z","updated_at":"2024-07-02T16:35:06.141Z","phase":"Phase 2","brief_title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","source_id_and_acronym":"NCT04191187","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 02/11/2024","primary_completion_date":" 02/11/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"}]